Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / How Umbilical Cord MSCs May Influence Inflammation in Ulcerative Colitis
Transcript
- 0:00SPEAKER_00: Welcome to the Cyrona Cell Podcast.
- 0:02SPEAKER_01: Thanks for having me.
- 0:03SPEAKER_01: It's uh it's great to be here to talk about this.
- 0:05SPEAKER_00: Yeah, absolutely.
- 0:06SPEAKER_00: So for today's mission, we're really taking a completely different perspective on how we approach, you know, chronic autoimmune conditions.
- 0:13SPEAKER_01: Right.
- 0:13SPEAKER_01: Getting away from just the standard symptom management.
- 0:16SPEAKER_00: Exactly.
- 0:16SPEAKER_00: We are specifically zeroing in on ulcerative colitis, or UC for short, and we're going on a deep dive to explore how um umbilical cord mesenchymal stem cells might actually hold the key to well, lowering inflammation in the gut.
- 0:32SPEAKER_01: Aaron Powell And not just by masking those symptoms, but by actually retraining the body's entire defense network, which is, you know, a massive shift in thinking.
- 0:41SPEAKER_00: It really is.
- 0:42SPEAKER_00: I mean, for you for you listening, we're taking all of this directly from materials provided by Cyrus Cell, which is a regenerative medicine center.
- 0:48SPEAKER_01: Right.
- 0:48SPEAKER_01: Because for the longest time, medicine has kind of looked at ulcerative colitis as just this um mechanical failure of the gut, like something that just needs to be forcefully suppressed.
- 0:59SPEAKER_00: Aaron Powell But the sources we're unpacking today, they highlight a biological approach that treats the gut more as the victim, right?
- 1:05SPEAKER_01: Aaron Powell Yeah, exactly.
- 1:07SPEAKER_01: The victim of a completely misguided immune system rather than the gut being the actual root source of the problem.
- 1:13SPEAKER_01: Aaron Powell Right.
- 1:13SPEAKER_00: And to give a little context on our sources, Cirona Cell is a doctor-led clinic based out of Cybergaya, Malaysia, which is just outside Kuala Lumpur.
- 1:21SPEAKER_01: Aaron Powell Yeah.
- 1:22SPEAKER_01: And they actually serve a really broad area.
- 1:24SPEAKER_00: Aaron Ross Powell They do.
- 1:25SPEAKER_00: They have a very global patient base, you know, people flying in from Australia, the Middle East, all over really for this medically supervised cell therapy.
- 1:34SPEAKER_01: Trevor Burrus And their name is actually pretty interesting, right?
- 1:36SPEAKER_00: Oh, yeah.
- 1:37SPEAKER_00: Sorona comes from a Celtic goddess of health and protection, which I think really signals their focus on um careful, science-led care rather than those, you know, wild quick fix promises you sometimes see popping up on the internet.
- 1:52SPEAKER_01: Aaron Powell Which is absolutely critical when you're talking about the regenerative medicine space.
- 1:55SPEAKER_01: I mean, what really stands out in their clinical approach is that they view this therapy as an adjunct.
- 2:00SPEAKER_01: Trevor Burrus, Jr.
- 2:00SPEAKER_00: An adjunct, meaning it works with what you're already doing.
- 2:04SPEAKER_01: Exactly.
- 2:05SPEAKER_01: They're very clear that this operates alongside your standard specialist care.
- 2:09SPEAKER_01: It's meant to communicate with your existing medical framework to target that root immune dysfunction.
- 2:15SPEAKER_00: Okay, so um, before we get into how they do that, I have to ask a big pushback question.
- 2:20SPEAKER_00: Sure, go for it.
- 2:21SPEAKER_00: When you throw the term stem cells out there, my mind immediately goes to, well, some highly controversial places.
- 2:28SPEAKER_01: Right.
- 2:28SPEAKER_01: People immediately think of embryos.
- 2:31SPEAKER_00: Exactly.
- 2:32SPEAKER_00: Are we talking about embryonic stem cells here?
- 2:34SPEAKER_00: Whose cells are these?
- 2:36SPEAKER_01: It's probably the most important question to clarify right up front.
- 2:39SPEAKER_01: We are absolutely not talking about embryonic stem cells.
- 2:42SPEAKER_00: Okay, that's a relief.
- 2:43SPEAKER_01: Yeah.
- 2:44SPEAKER_01: And we aren't discussing those experimental lab-created plu pluripotent cells either.
- 2:49SPEAKER_01: The protocols at Cirona Cell utilize ethically sourced WJMSCs.
- 2:54SPEAKER_00: Okay, WJMSCs, you're gonna have to break that down for me.
- 2:56SPEAKER_01: Aaron Powell Right.
- 2:57SPEAKER_01: So the WJ stands for Wharton's Jelly.
- 3:00SPEAKER_00: Or Wharton's Jelly.
- 3:01SPEAKER_01: Yeah.
- 3:01SPEAKER_01: It's this gelatinous tissue that basically surrounds and protects the blood vessels inside a human umbuccal cord.
- 3:06SPEAKER_00: Oh wow.
- 3:07SPEAKER_00: Okay.
- 3:07SPEAKER_01: So after a healthy full-term baby is born, and you know, only with the explicit prior consent of the donor mother, this cord is collected.
- 3:16SPEAKER_00: Aaron Powell So it's from healthy births.
- 3:17SPEAKER_01: Exactly.
- 3:18SPEAKER_01: Historically, hospitals just incinerated this as medical waste.
- 3:22SPEAKER_01: So it's collected with zero harm to the mother or the child.
- 3:25SPEAKER_00: Aaron Powell So we're taking this discarded tissue and extracting the mesenchymal stem cells, the MSCs, from it.
- 3:32SPEAKER_01: Yep.
- 3:32SPEAKER_01: That's the process.
- 3:33SPEAKER_00: Aaron Ross Powell But I mean, I know you can get stem cells from a patient's own bone marrow, right?
- 3:38SPEAKER_00: Or even their body fat.
- 3:40SPEAKER_00: So why use the umbilical cord?
- 3:42SPEAKER_01: Well, it really comes down to marrow cells have been studied for decades, but getting them requires literally drilling into bone.
- 3:52SPEAKER_00: Uh which sounds incredibly painful.
- 3:53SPEAKER_01: Aaron Powell It is a very painful invasive extraction.
- 3:56SPEAKER_01: And biologically, think about it.
- 3:58SPEAKER_01: If you're pulling cells from a 40-year-old patient, those stem cells are also 40 years old.
- 4:03SPEAKER_00: Oh, right.
- 4:03SPEAKER_00: I never thought about that.
- 4:04SPEAKER_01: Aaron Ross Powell Yeah, they've been exposed to environmental toxins, stress, and whatever illness the patient is currently fighting.
- 4:10SPEAKER_01: Trevor Burrus, Jr.
- 4:10SPEAKER_00: So they're kind of beat up already.
- 4:11SPEAKER_01: Aaron Powell Exactly.
- 4:12SPEAKER_01: And fat-derived cells, well, they're easier to extract, but they just don't possess the same potent anti-inflammatory properties.
- 4:19SPEAKER_00: Trevor Burrus, Jr.
- 4:19SPEAKER_00: Okay.
- 4:19SPEAKER_00: So if bone marrow cells are like the older, tired workers who need to be dragged out of bed to do a job.
- 4:26SPEAKER_01: Yeah.
- 4:26SPEAKER_01: That's a good way to put it.
- 4:27SPEAKER_00: Aaron Powell And fat cells are maybe the weaker workers, then the umbilical cord cells from Wharton's jelly are basically the energetic new recruits.
- 4:35SPEAKER_01: Aaron Powell They are.
- 4:36SPEAKER_01: They're essentially day zero cells.
- 4:38SPEAKER_01: Because they're so young, they divide much faster in culture, and they secrete massively higher levels of these healing factors that we're going to discuss.
- 4:46SPEAKER_00: That makes a lot of sense.
- 4:47SPEAKER_01: And um siren cell actually utilizes what are called early passage cells, all processed in CGMP and BSL2 certified labs.
- 4:56SPEAKER_00: Aaron Powell Okay, pause.
- 4:57SPEAKER_00: What does early passage mean?
- 4:58SPEAKER_00: And then you'll have to translate those acronyms for me.
- 5:00SPEAKER_01: Ha, fair enough.
- 5:01SPEAKER_01: So early passage means the cells haven't been forced to replicate hundreds of times in a petri dish.
- 5:07SPEAKER_00: Oh, like making copies of a copy.
- 5:09SPEAKER_01: Exactly.
- 5:09SPEAKER_01: If you photocopy a document too many times, the text gets blurry.
- 5:13SPEAKER_01: It's the same with cells.
- 5:14SPEAKER_01: Early passage ensures they keep their original potent biological programming.
- 5:19SPEAKER_01: Got it.
- 5:20SPEAKER_00: And the lab certifications.
- 5:21SPEAKER_01: Right.
- 5:21SPEAKER_01: So CGMP stands for current good manufacturing practice.
- 5:25SPEAKER_01: It's a strict international standard for quality control.
- 5:28SPEAKER_01: Okay.
- 5:29SPEAKER_01: And BSL2 is biosafety level two, meaning they have really rigorous safeguards against contamination.
- 5:36SPEAKER_01: Every batch gets obsessive testing for identity, sterility, and viability before it ever touches a patient.
- 5:42SPEAKER_00: That's reassuring.
- 5:43unknown: Yeah.
- 5:44SPEAKER_00: You definitely want a clean, verified recruit.
- 5:46SPEAKER_01: Absolutely.
- 5:47SPEAKER_00: And because they are newborn cells, my understanding from the materials is that you don't even need to be a genetic match to receive them, right?
- 5:54SPEAKER_00: They just fly right under the recipient's immune radar.
- 5:56SPEAKER_01: Yeah, they have very low immune reactivity.
- 5:58SPEAKER_00: But here is where my brain just gets stuck.
- 6:00SPEAKER_00: The delivery method for this therapy is typically just a minimally invasive IV drip.
- 6:05SPEAKER_01: Right.
- 6:06SPEAKER_01: Standard IV.
- 6:07SPEAKER_00: So the cells just go straight into a vein in your arm.
- 6:10SPEAKER_00: But the circulatory system is this massive rushing highway.
- 6:15SPEAKER_00: How in the world do cells in my arm know they're supposed to go fix the ulcers in my colon?
- 6:20SPEAKER_01: It's a great question.
- 6:21SPEAKER_00: I mean, why don't they just end up parked to my liver or something?
- 6:24SPEAKER_01: Well, this brings us to one of the most elegant mechanisms in human biology.
- 6:28SPEAKER_01: It's a process called homing.
- 6:30SPEAKER_00: Combing.
- 6:30SPEAKER_01: Yeah.
- 6:31SPEAKER_01: And it relies entirely on a chemical gradient.
- 6:34SPEAKER_00: A chemical gradient, like um like following a scent trail.
- 6:37SPEAKER_01: Very much like that.
- 6:38SPEAKER_01: When the tissue in the colon is being attacked and damaged by the immune system in UC, those dying cells don't just suffer quietly.
- 6:46SPEAKER_00: They make some noise.
- 6:47SPEAKER_01: They do.
- 6:47SPEAKER_01: They release severe distress signals into the surrounding blood vessels.
- 6:52SPEAKER_01: Specifically, they secrete a highly potent molecule called CXCL12.
- 6:56SPEAKER_00: Okay, let's unpack this.
- 6:57SPEAKER_00: Think of CXCL12 as a microscopic chemical flare, or like a 911 call from the gut.
- 7:04SPEAKER_01: That's spot on.
- 7:04SPEAKER_01: So the colon is popping these flares and the chemical is washing out into the bloodstream.
- 7:09SPEAKER_01: Now, those umbilical cord stem cells are uniquely equipped with specialized surface receptors.
- 7:14SPEAKER_00: Like little antennas.
- 7:15SPEAKER_01: Exactly.
- 7:16SPEAKER_01: The primary one is called CXCR4.
- 7:19SPEAKER_01: You can visualize it just like an antenna sticking out of the stem cell, specifically tuned to detect that exact CXCL12 flare.
- 7:28SPEAKER_00: That is just fascinating.
- 7:30SPEAKER_00: So as these energetic new recruits are tumbling through the rushing river of your bloodstream, their antennas pick up this 9-11 signal.
- 7:38SPEAKER_01: Yep.
- 7:38SPEAKER_00: But how does that actually make them stop?
- 7:40SPEAKER_00: I mean, they're moving fast.
- 7:41SPEAKER_00: How do they exit the highway?
- 7:43SPEAKER_01: Well, as the stem cell circulates closer to the colon, the concentration of that distress chemical gets thicker and thicker in the blood.
- 7:50SPEAKER_00: Oh, so the scent gets stronger.
- 7:51SPEAKER_01: Exactly.
- 7:52SPEAKER_01: Once those antennas detect a high enough concentration, the stem cell actually physically alters its shape.
- 7:58SPEAKER_00: Wait, really?
- 7:58SPEAKER_01: Yeah, it flattens out, grips the endothelial wall of the blood vessel, and actively squeezes itself out of the bloodstream and directly into the inflamed colonic tissue.
- 8:07SPEAKER_00: Just pulls itself right through the wall.
- 8:08SPEAKER_01: It literally pulls itself toward the heaviest fighting.
- 8:11SPEAKER_00: Wow.
- 8:12SPEAKER_00: They are literally microscopic first responders.
- 8:14SPEAKER_01: They really are.
- 8:15SPEAKER_00: But wait, I was reading through the Nature Scientific Report study, included in our source stack, and um, I need you to clarify something because it completely upended how I thought this worked.
- 8:25SPEAKER_01: Okay.
- 8:26SPEAKER_01: What was it?
- 8:26SPEAKER_00: These stem cells.
- 8:28SPEAKER_00: Well, they don't actually move into the colon, plant themselves in the wall, and become terminant gut tissue, do they?
- 8:34SPEAKER_01: No.
- 8:35SPEAKER_01: No, they do not.
- 8:36SPEAKER_01: And this is perhaps the biggest misconception surrounding regenerative medicine for autoimmune conditions.
- 8:41SPEAKER_00: But people think it's like planting seeds.
- 8:43SPEAKER_01: Exactly.
- 8:44SPEAKER_01: But it's not about physically replacing damaged organs like putting a new alternator in a car.
- 8:50SPEAKER_01: It's almost entirely about paracrine signaling.
- 8:53SPEAKER_01: Yeah.
- 8:54SPEAKER_01: Which basically means cell-to-cell communication.
- 8:56SPEAKER_00: Aaron Powell Because the study showed that scientists could take just the MSC extract, right?
- 9:01SPEAKER_00: Like basically just the chemical broth the cells secrete without any actual physical cells in it at all.
- 9:07SPEAKER_01: Exactly.
- 9:07SPEAKER_00: And they gave it to lab mice with colitis and saw almost the exact same healing response.
- 9:12SPEAKER_01: Aaron Powell Which is the smoking gun, really?
- 9:14SPEAKER_01: It proves that the magic isn't in the cell physically becoming a new piece of your colon.
- 9:19SPEAKER_01: The magic is in the incredibly complex microscopic orders.
- 9:23SPEAKER_01: Those cells are shouting to your existing immune system once they arrive on the battlefield.
- 9:28SPEAKER_00: Okay, so they roll up to the inflamed colon, they take a look at the chaos, and they just start barking orders.
- 9:34SPEAKER_01: Yep.
- 9:35SPEAKER_01: They take charge.
- 9:36SPEAKER_00: So let's get into the weeds here.
- 9:37SPEAKER_00: What exactly are they saying and who are they talking to?
- 9:40SPEAKER_00: Let's talk about these microscopic peacekeepers.
- 9:42SPEAKER_01: So to understand the orders being given, we first have to look at the culprits driving the ulcerative colitis riot in the first place.
- 9:48SPEAKER_00: The bad guys.
- 9:49SPEAKER_01: Right.
- 9:50SPEAKER_01: In your immune system, T cells are the generals.
- 9:53SPEAKER_01: And in UC, a specific class called T helper cells, specifically TH1 and TH17, have gone completely rogue.
- 10:01SPEAKER_00: So TH1 and TH17 are the guys with the megaphones inciting the riot.
- 10:05SPEAKER_01: Exactly.
- 10:06SPEAKER_01: They were the ones flooding the gut with pro-inflammatory cytokines, just hyping up the attack.
- 10:11SPEAKER_00: But doesn't the body have a way to shut them down normally?
- 10:14SPEAKER_00: I mean, we aren't all walking around with inflamed colons.
- 10:16SPEAKER_01: It does.
- 10:17SPEAKER_01: You have a counterforce called regulatory T cells, or T regs.
- 10:20SPEAKER_01: Their entire job is to hit the brakes and enforce tolerance.
- 10:24SPEAKER_01: Okay.
- 10:24SPEAKER_01: But in a UC patient, the riot has basically overpowered the police.
- 10:28SPEAKER_01: The pro-inflammatory cells are wildly overactive, and the regulatory T cells are suppressed and just totally exhausted.
- 10:36SPEAKER_00: Wow.
- 10:36SPEAKER_00: So our energetic recruits from the umbilical cord arrive via that homing beacon.
- 10:41SPEAKER_00: How do they break up the fight?
- 10:42SPEAKER_01: Aaron Ross Powell The MSCs act like a localized chemical factory.
- 10:46SPEAKER_01: Once they're there, they begin pumping out the specific alphabet soup of immune modulating molecules.
- 10:52SPEAKER_00: Oh, here come the acronyms again.
- 10:53SPEAKER_01: Yeah.
- 10:53SPEAKER_01: The major players are PGE2, TGF beta, and an enzyme called IDO.
- 10:58SPEAKER_00: Aaron Powell Okay, let's break those down.
- 10:59SPEAKER_00: What is that chemical bat actually doing to the riot?
- 11:02SPEAKER_01: Aaron Powell It works on two fronts simultaneously.
- 11:04SPEAKER_01: When those rogue TH1 and TH17 cells are bathed in molecules like TGF beta and IDO, it essentially acts as a molecular gag order.
- 11:13SPEAKER_00: Aaron Powell A gag order.
- 11:14SPEAKER_00: I like that.
- 11:14SPEAKER_01: Yeah.
- 11:15SPEAKER_01: It physically binds to the receptors and alters their internal signaling, basically forcing them to power down and start producing inflammation.
- 11:21SPEAKER_00: So it takes away their megaphones.
- 11:23SPEAKER_01: Exactly.
- 11:24SPEAKER_01: And at the exact same time, that same chemical bath acts as a massive stimulant for the patient's native regulatory T cells.
- 11:32SPEAKER_00: The peacekeepers.
- 11:33SPEAKER_01: Right.
- 11:33SPEAKER_01: It causes those exhausted peacekeepers to rapidly multiply.
- 11:37SPEAKER_00: Okay.
- 11:37SPEAKER_00: So they mute the rioters and multiply the peacekeepers.
- 11:40SPEAKER_00: That's incredible.
- 11:40SPEAKER_01: It is.
- 11:41SPEAKER_01: But it actually goes deeper than T cells.
- 11:44SPEAKER_01: We also have to talk about macrophages.
- 11:46SPEAKER_00: Macrophages.
- 11:46SPEAKER_01: Yeah.
- 11:47SPEAKER_01: These are the white blood cells that act as the gut's frontline security guards.
- 11:50SPEAKER_01: They actually roam around eating cellular debris and bacteria.
- 11:54SPEAKER_01: Aaron Powell Yeah.
- 11:55SPEAKER_00: From what I saw in the research, it looks like they have two distinct personalities, right?
- 11:59SPEAKER_00: Yeah.
- 11:59SPEAKER_00: Like an M1 and an M2.
- 12:01SPEAKER_01: That is correct.
- 12:02SPEAKER_01: M1 is the attack and destroy mode.
- 12:04SPEAKER_01: M2 is the cleanup and repair mode.
- 12:06SPEAKER_00: Okay, so they switch back and forth.
- 12:07SPEAKER_01: In a healthy person, yes.
- 12:09SPEAKER_01: A macrophage will switch to M1 to kill a bacteria, and then switch to M2 to clean up the mess and heal the tissue.
- 12:16SPEAKER_00: But in ulcerative colitis.
- 12:17SPEAKER_01: And you see those macrophages are permanently stuck in M1 attack mode.
- 12:22SPEAKER_00: Oh no.
- 12:22SPEAKER_01: Yeah, they become jagged, aggressive, and they constantly spit out highly damaging signals.
- 12:28SPEAKER_00: Are those the signals the sources mentioned?
- 12:30SPEAKER_00: Yeah.
- 12:30SPEAKER_00: Um MCP-1 and ionos?
- 12:33SPEAKER_01: Yes.
- 12:33SPEAKER_01: Think of those as essentially molecular acid.
- 12:36SPEAKER_01: They're breaking down the surrounding tissue to attack a threat that isn't really there.
- 12:40SPEAKER_00: Wow.
- 12:41SPEAKER_00: So if the macrophages are the security guards, in UC, they are completely hypervigilant.
- 12:47SPEAKER_00: They think the building itself is the threat, so they're just smashing the walls.
- 12:50SPEAKER_01: That's a perfect way to visualize it.
- 12:52SPEAKER_00: So how do the stem cells fix a macrophage that's stuck in attack mode?
- 12:56SPEAKER_01: Through a process called repolarization.
- 12:58SPEAKER_00: Repolarization.
- 12:59SPEAKER_01: Right.
- 12:59SPEAKER_01: When the MSCs release factors like PGE2, it docks onto the surface of that stuck M1 macrophage.
- 13:06SPEAKER_01: This docking triggers a cascade inside the macrophage's nucleus, literally forcing it to change its gene expression.
- 13:13SPEAKER_00: It reprograms it on the spot.
- 13:14SPEAKER_01: It physically alters its shape, stops producing that molecular acid, and switches it into M2 mode.
- 13:19SPEAKER_00: So the stem cell basically walks up to the hypervigilant security guard, taps him on the shoulder, tells him to drop the sledgehammer, and hands them a broom.
- 13:28SPEAKER_01: A broom in a first aid kit, really.
- 13:29SPEAKER_01: Because once they're in M2 mode, those macrophages start pumping out IL-10.
- 13:33SPEAKER_00: IL-10.
- 13:34SPEAKER_00: What is that?
- 13:35SPEAKER_01: Interleukin.
- 13:36SPEAKER_01: It is one of the human body's most powerful anti-inflammatory cytokines.
- 13:42SPEAKER_01: It's essentially heavy-duty fire retardant.
- 13:45SPEAKER_01: Oh wow.
- 13:46SPEAKER_01: And if we connect this to the bigger picture, this right here is why MSC therapy is fundamentally different from taking a standard immunosuppressant pill.
- 13:54SPEAKER_00: Because a pill just suppresses everything.
- 13:56SPEAKER_01: Exactly.
- 13:56SPEAKER_01: A pill just acts like a blanket, smothering your entire immune system while the drug is circulating in your bloodstream.
- 14:02SPEAKER_01: But the stem cells are interacting dynamically.
- 14:05SPEAKER_01: They are actively retraining your own T cells and macrophages to behave correctly again.
- 14:10SPEAKER_00: That is a brilliant distinction.
- 14:12SPEAKER_00: It's not suppression, it's education.
- 14:14SPEAKER_01: Precisely.
- 14:14SPEAKER_00: Okay, so the stem cells have navigated to the gut, they've multiplied the regulatory peacekeepers, and they've handed brooms to the macrophage security guards.
- 14:23SPEAKER_00: The riot is over.
- 14:24SPEAKER_01: The riot is over.
- 14:26SPEAKER_00: But we still have a major problem, right?
- 14:27SPEAKER_00: The colon is still physically destroyed from the riot.
- 14:30SPEAKER_00: The walls are in ruins.
- 14:32SPEAKER_01: And if you don't rebuild the wall, the whole cycle will just start over.
- 14:35SPEAKER_01: You have to repair what we call the intestinal epithelial barrier.
- 14:38SPEAKER_00: Describe this barrier for me.
- 14:40SPEAKER_00: I mean, what are we actually looking at under the microscope?
- 14:43SPEAKER_01: The lining of your colon is incredibly fragile.
- 14:46SPEAKER_01: It's actually just a single layer of epithelial cells.
- 14:50SPEAKER_01: One single cell thick.
- 14:52SPEAKER_00: That's it.
- 14:53SPEAKER_00: Just one cell thick.
- 14:54SPEAKER_01: That's it.
- 14:55SPEAKER_01: That microscopic layer is the only thing standing between the sterile environment of your bloodstream and a colon filled with trillions of bacteria.
- 15:03SPEAKER_00: That sounds precarious.
- 15:04SPEAKER_01: It is.
- 15:05SPEAKER_01: These cells are glued tightly together by proteins called tight junctions.
- 15:09SPEAKER_00: Okay, so I picture it like a brick wall, and those tight junctions are the mortar holding the bricks flush against each other.
- 15:15SPEAKER_01: Perfect visual.
- 15:16SPEAKER_01: In ulcerative colitis, the constant inflammation acts like a pressure washer, completely blasting away that mortar.
- 15:22SPEAKER_01: The tight junctions disintegrate.
- 15:24SPEAKER_00: And when the mortar washes away, gaps open up, which means all those trillions of bacteria inside the colon suddenly have an open door into the tissue beneath the wall.
- 15:34SPEAKER_01: Which instantly trips the immune system's alarm all over again.
- 15:37SPEAKER_01: It's this vicious, self-reinforcing cycle.
- 15:39SPEAKER_00: Aaron Powell So the standard drugs might put out the fire, but they don't fix the wall.
- 15:43SPEAKER_01: Right.
- 15:43SPEAKER_01: A lot of standard drugs are great at reducing the inflammation, but they don't actively bring new mortar to the construction site.
- 15:50SPEAKER_00: Aaron Powell Which is where our umbilical cord cells step up for part two of their emission.
- 15:55SPEAKER_00: So how do they physically rebuild this wall?
- 15:58SPEAKER_01: The MSCs release a totally different set of signals this time, highly specific growth factors.
- 16:03SPEAKER_01: The big three are HGF, EGF, and VEGF.
- 16:06SPEAKER_00: Okay, alphabet soup time again.
- 16:08SPEAKER_00: What do these growth factors actually do?
- 16:11SPEAKER_01: Think of them as blueprints and supplies for different contractors.
- 16:15SPEAKER_01: HGF is a parasite growth factor.
- 16:17SPEAKER_01: It promotes cell migration.
- 16:18SPEAKER_00: Migration, like moving cells around.
- 16:20SPEAKER_01: Yeah, it essentially tells surviving healthy epithelial cells to stretch out and move across the gaps to cover the exposed tissue.
- 16:27SPEAKER_00: Oh, like pulling a tarp over a hole in the roof.
- 16:29SPEAKER_01: Exactly.
- 16:29SPEAKER_01: Then you have EGF, epidermal growth factor.
- 16:32SPEAKER_01: This stimulates cellular proliferation.
- 16:34SPEAKER_01: It commands the tissue to generate brand new epithelial cells to permanently replace the ones that died.
- 16:40SPEAKER_00: So laying down the new bricks.
- 16:41SPEAKER_01: Yep.
- 16:42SPEAKER_01: And finally, VEGF, vascular endothelial growth factor.
- 16:45SPEAKER_00: Vascular implies blood vessels, right?
- 16:47SPEAKER_01: Yes.
- 16:48SPEAKER_01: VEGF signals the body to build tiny new blood capillaries in the damaged area.
- 16:53SPEAKER_01: Healing tissue requires massive amounts of oxygen and nutrients.
- 16:56SPEAKER_01: VEGF builds the supply lines to feed the construction site.
- 17:01SPEAKER_00: This is wild.
- 17:02SPEAKER_00: So they're pulling tarps over the holes, laying down brand new bricks, and building roads to bring in supplies.
- 17:08SPEAKER_01: Pretty much.
- 17:09SPEAKER_00: And I saw in the Serenicell materials that they also heavily support something called mucin production.
- 17:14SPEAKER_01: Oh, yeah.
- 17:15SPEAKER_01: That's crucial.
- 17:16SPEAKER_00: What is mucin and why does it matter?
- 17:18SPEAKER_01: Mucin is the primary component of mucus.
- 17:21SPEAKER_01: In a healthy gut, a really thick layer of mucus coats the entire epithelial wall.
- 17:25SPEAKER_01: Okay.
- 17:26SPEAKER_01: It's the absolute first line of physical defense, keeping the bacteria from even touching the cells.
- 17:31SPEAKER_01: By stimulating the goblet cells in the gut to pump out fresh mucin, the MSCs are essentially applying a thick, waterproof sealant over the newly repaired brick wall.
- 17:40SPEAKER_00: Wow.
- 17:41SPEAKER_00: So biologically we have a complete masterpiece happening here.
- 17:44SPEAKER_01: It really is.
- 17:45SPEAKER_00: The cells home in on the distress signal, they retrain the rogue immune cells, they generate new tissue, and they seal it all up.
- 17:52SPEAKER_00: But you know, let's bring this out of the microscope and into the clinic.
- 17:55SPEAKER_00: For you listening, how does this actually translate to a human being living with ulcerative colitis?
- 18:01SPEAKER_00: How do doctors actually measure if this is working?
- 18:05SPEAKER_01: The gold standard for measuring success in clinical trials is the disease activity index, or DAI.
- 18:11SPEAKER_00: Okay, DAI.
- 18:12SPEAKER_01: Right.
- 18:12SPEAKER_01: It's a composite score.
- 18:13SPEAKER_01: It isn't just about the patient subjectively saying, I feel better.
- 18:17SPEAKER_00: They need hard numbers.
- 18:18SPEAKER_01: Exactly.
- 18:18SPEAKER_01: The DAI measures physical metrics, stool consistency, the frequency of bleeding, unintended weight changes, and the visual state of the colon.
- 18:26SPEAKER_01: The lower the DAI score, the closer you are to normal.
- 18:29SPEAKER_00: And what does the data actually show when patients receive these umbilical cord MSCs?
- 18:35SPEAKER_01: The human clinical data is very compelling.
- 18:38SPEAKER_01: Trials consistently report a 60 to 75% clinical response rate.
- 18:42SPEAKER_00: That's a huge response rate.
- 18:44SPEAKER_01: It is.
- 18:44SPEAKER_01: That means a significant drop in that DAI score for the majority of patients.
- 18:48SPEAKER_01: But more impressively, between 25 to 50% of patients achieve full clinical remission at the three-month mark.
- 18:55SPEAKER_00: And clinical remission isn't just an absence of pain, right?
- 18:58SPEAKER_01: No, it's confirmed by endoscopy.
- 19:01SPEAKER_01: A gastroenterologist goes in with a camera and visibly confirms mucosal healing.
- 19:06SPEAKER_01: The ulcers are gone, the wall is intact.
- 19:08SPEAKER_01: That is amazing.
- 19:09SPEAKER_01: Furthermore, if you pull blood work from these patients, you see a dramatic plunge in major inflammatory markers.
- 19:16SPEAKER_01: Things like CRP and ESR, which measure systemic inflammation, they just drop significantly.
- 19:23SPEAKER_01: Specific cytokine markers like TNF alpha and IL6 also plummet.
- 19:27SPEAKER_00: Those are basically the smoke alarms in the bloodstream, and you can literally measure the smoke clearing out.
- 19:32SPEAKER_01: That's a great way to put it.
- 19:33SPEAKER_00: But here's the critical question for anyone considering this therapy at a place like Cyrenusel.
- 19:38SPEAKER_00: Sure.
- 19:38SPEAKER_00: What is the long game here?
- 19:40SPEAKER_00: I mean, it is wonderful to heal at three months, but what happens at month 12?
- 19:43SPEAKER_00: Does the immune system just forget the training and go rogue again?
- 19:47SPEAKER_01: That is the beauty of immune retraining versus temporary suppression.
- 19:50SPEAKER_01: Because the MSC has expanded your regulatory T cells and repolarized your macrophages, the benefits are incredibly durable.
- 19:58SPEAKER_00: So it lasts.
- 19:58SPEAKER_01: Yes.
- 19:59SPEAKER_01: Long-term follow-up data shows that for patients who respond well, the clinical benefits often persist for twelve to twenty-four months after a single treatment cycle.
- 20:08SPEAKER_00: Aaron Powell Up to two years of a calmed immune system from a therapy that essentially washes out of your body in a few weeks.
- 20:15SPEAKER_01: Yes, because the stem cells themselves don't stick around, but the education they provided to your native cells remains.
- 20:21SPEAKER_00: That's the retraining part.
- 20:22SPEAKER_01: Exactly.
- 20:23SPEAKER_01: And crucially, this long-term remission comes without the cumulative risks of standard heavy immunosuppressants.
- 20:30SPEAKER_00: Right, because those can have harsh side effects.
- 20:32SPEAKER_01: If you're on heavy biologics or steroids for years, you face cumulative risks of severe opportunistic infections or even certain malignancies.
- 20:40SPEAKER_01: MSC therapy avoids that toxic compounding effect.
- 20:44SPEAKER_00: Which brings up an interesting point.
- 20:45SPEAKER_00: Can a patient do this if they are currently taking those standard medications?
- 20:50SPEAKER_01: Absolutely.
- 20:50SPEAKER_01: At clinics like Ceranocel, this is strictly positioned as an adjunct therapy.
- 20:54SPEAKER_00: So they work together.
- 20:55SPEAKER_01: In most cases, patients continue their existing biologics or anti-inflammatory meds while receiving stem cells.
- 21:02SPEAKER_01: The medical team reviews the file to ensure there are no direct negative interactions.
- 21:07SPEAKER_00: Like what?
- 21:08SPEAKER_01: Well, for instance, extremely high doses of corticosteroids might inhibit the stem cells from functioning properly, so timing is key.
- 21:16SPEAKER_01: But the ultimate long-term goal for many patients, in coordination with their primary gastroenterologist, is to use the cellular healing to eventually taper down those harsh standard medications.
- 21:28SPEAKER_00: That makes total sense.
- 21:29SPEAKER_00: And because this therapy is systemic, meaning the IV drip puts the cells into your entire circulatory system, it seems like there would be massive secondary benefits.
- 21:38SPEAKER_00: Ulcerative colitis is famous for causing outside the gut symptoms, right?
- 21:42SPEAKER_01: Oh, it really is.
- 21:43SPEAKER_01: The same rogue immune cells damaging the colon often circulate and cause severe joint pain, skin rashes, or even eye inflammation.
- 21:49SPEAKER_01: Right.
- 21:50SPEAKER_01: Because the stem cells are circulating everywhere, they can detect those secondary chemical flares and calm inflammation systemically.
- 21:56SPEAKER_01: This shared mechanism of action is exactly why these same WJMSCs are actively being studied and utilized for Crohn's disease as well.
- 22:05SPEAKER_01: Plus, once you drop the systemic inflammation, your gut microbiome, the good bacteria, finally has a hospitable environment to re-establish itself.
- 22:14SPEAKER_00: Which aids in digestion and just overall health.
- 22:16SPEAKER_01: Exactly.
- 22:17SPEAKER_00: It really is treating the entire ecosystem of the body rather than just patching the broken pipe.
- 22:21SPEAKER_01: It's a total paradigm shift.
- 22:22SPEAKER_00: So to bring it all together for you listening, we start with these energetic day zero umbilical cord cells, rigorously and ethically prepared at regenerative centers like Cironacell.
- 22:33SPEAKER_01: Yep.
- 22:34SPEAKER_00: They enter your bloodstream, pick up on the chemical distress signals radiating from your colon, and navigate straight to the war zone.
- 22:41SPEAKER_00: They don't become your colon.
- 22:43SPEAKER_00: Instead, they act as master communicators.
- 22:46SPEAKER_00: Right.
- 22:46SPEAKER_00: They mute the rioting T cells, they hand brooms to the macrophage security guards, and they release growth factors to physically lay new bricks and seal the gut wall, leading to deep, measurable, and durable remission.
- 22:59SPEAKER_01: And you know, when you look at the sheer intelligence of that cellular communication, it opens up a fascinating, almost science fiction level question for the future of medicine.
- 23:08SPEAKER_00: Oh, what's that?
- 23:09SPEAKER_01: Well, we just spent this entire time talking about how these cells use a chemical gradient to cross out of the bloodstream and into the inflamed tissue of the gut.
- 23:18SPEAKER_00: Right, the homing mechanism.
- 23:19SPEAKER_01: Exactly.
- 23:20SPEAKER_01: But researchers are now looking at other seemingly impenetrable barriers in the body.
- 23:25SPEAKER_01: If these WJMSCs are this incredibly adept at tracking down local inflammation and resetting rogue immune cells, could this same exact homing mechanism eventually be utilized to cross the blood-brain barrier?
- 23:39SPEAKER_00: Wow.
- 23:39SPEAKER_01: Could we one day use these newborn cells to track down and reset the neuroinflammation driving diseases like Parkinson's or Alzheimer's?
- 23:47SPEAKER_01: It suggests that the gut might just be the proving ground for a much larger revolution in how we heal the human brain.
- 23:53SPEAKER_00: Crossing the blood-brain barrier with targeted biological peacekeepers.
- 23:56SPEAKER_00: That is a phenomenal thought to end on, and really a perfect example of why this field is moving so incredibly fast.
- 24:03SPEAKER_01: It's an exciting time for medicine.
- 24:04SPEAKER_00: It really is.
- 24:06SPEAKER_00: The body has the capacity to remember how to heal.
- 24:08SPEAKER_00: Sometimes it just needs the right microscopic translation to get back on track.
- 24:13SPEAKER_00: Thank you for joining us on this deep dive into the science of regenerative medicine.
- 24:17SPEAKER_00: Keep asking questions, keep exploring the research, and we'll catch you next time.